scholarly journals Image Gallery: Peculiar subungual localization of a second primary melanoma during BRAF inhibitors treatment for metastatic melanoma: case report

2019 ◽  
Vol 180 (5) ◽  
Author(s):  
A. Ventura ◽  
R. Pitocco ◽  
A. Di Stefani ◽  
C. Cota ◽  
D. Spallone ◽  
...  
Keyword(s):  
Case Report ◽  
Metastatic Melanoma ◽  
Primary Melanoma ◽  
Second Primary ◽  
Braf Inhibitors ◽  
Melanoma Case

PO.32 OCCULT GASTROINTESTINAL BLEEDING DUE TO JEJUNAL METASTATIC MELANOMA: CASE REPORT

2008 ◽  
Vol 40 ◽  
pp. S182
Author(s):  
F. Vadilonga ◽  
A. Loriga ◽  
A. Atzei ◽  
F. Miculan ◽  
S. Bergamini ◽  
...  
Keyword(s):  
Case Report ◽  
Gastrointestinal Bleeding ◽  
Metastatic Melanoma ◽  
Occult Gastrointestinal Bleeding ◽  
Melanoma Case

Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature

2010 ◽  
Vol 42 (4) ◽  
pp. 302-306 ◽  
Author(s):  
Cosimo Sperti ◽  
Maria Laura Polizzi ◽  
Valentina Beltrame ◽  
Margherita Moro ◽  
Sergio Pedrazzoli
Keyword(s):  
Case Report ◽  
Metastatic Melanoma ◽  
Pancreatic Resection ◽  
Review Of The Literature ◽  
Melanoma Case

Pigmentation of axillary sentinel nodes from extensive skin tattoo mimics metastatic melanoma: case report

2013 ◽  
Vol 53 (6) ◽  
pp. 773-776 ◽  
Author(s):  
Ausilia Maria Manganoni ◽  
Elena Sereni ◽  
Giacomo Pata ◽  
Marco Ungari ◽  
Laura Pavoni ◽  
...  
Keyword(s):  
Case Report ◽  
Metastatic Melanoma ◽  
Sentinel Nodes ◽  
Melanoma Case

P-05-015 Penile primary melanoma. Case report.

2016 ◽  
Vol 13 (5) ◽  
pp. S222
Author(s):  
L. de Verdonces ◽  
N. Hannaoui ◽  
R. Martos ◽  
R. Ballester ◽  
Y. Fadil ◽  
...  
Keyword(s):  
Case Report ◽  
Primary Melanoma ◽  
Melanoma Case

scholarly journals TRICHILEMMAL CYSTIS IN METASTATIC MELANOMA: A CASE REPORT

2017 ◽  
Vol 39 (1) ◽  
pp. 86-87
Author(s):  
I Savarese ◽  
M Grazzini ◽  
A Gori ◽  
A D’Errico ◽  
L Doni ◽  
...  
Keyword(s):  
Case Report ◽  
Systemic Sclerosis ◽  
Malignant Melanoma ◽  
Brain Metastasis ◽  
Metastatic Melanoma ◽  
Primary Melanoma ◽  
Paraneoplastic Syndromes ◽  
Frontal Region ◽  
Unknown Primary ◽  
Paraneoplastic Pemphigus

The malignant melanoma is a neoplasm associated with a wide variety of cutaneous paraneoplastic syndromes, as dermatomyositis, systemic sclerosis, paraneoplastic pemphigus. We describe a case of four multiple trichilemmal cystis arising on frontal region in the same patient with brain metastasis and unknown primary melanoma and discuss their relationship.

Second primary melanoma on a patient undergoing vemurafenib therapy. A case report

2017 ◽  
Vol 56 (7) ◽  
pp. 792-794 ◽  
Author(s):  
Giuliana Onnis ◽  
Giuseppe Palmieri ◽  
Maria Antonietta Montesu ◽  
Rosanna Satta
Keyword(s):  
Case Report ◽  
Primary Melanoma ◽  
Second Primary

scholarly journals Clinicohistopathological Characteristics of Malignant Melanoma in the Gall Bladder: A Case Report and Review of the Literature

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Schmidt Adrian ◽  
Caspar Clemens ◽  
Schmidt-Weiss Elisabeth ◽  
Stadlmann Sylvia
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Gall Bladder ◽  
Metastatic Melanoma ◽  
Primary Melanoma ◽  
Review Of The Literature ◽  
Melanoma Patients

Objective. Primary gall bladder melanoma is a rare and controversial entity. So far, only 36 cases are documented in the literature. Metastatic melanoma targeting the gall bladder, however, has been reported to occur in about 15–20% of melanoma patients and is much more common. Methods. Based on the case of a 58-year-old woman presenting with multiple melanoma nodules in the gall bladder, we searched in the available literature in PubMed for articles describing a “primary melanoma of the gallbladder” regardless of language used. Results. We detected 33 papers that described 36 cases of primary gall bladder melanoma between 1907 and 2017. From different criteria distinguishing primary and secondary gall bladder melanoma, generally, the following were accepted: (1) exclusion of previous primary melanoma, (2) absence of synchronous involvement of other sites, (3) unicity of the lesion, (4) polypoid or papillary shape of the lesion, and (5) presence of junctional melanocitary component. Review of the 36 published cases revealed that only about one-fourth of them fulfilled all the five criteria. Conclusion. Primary gall bladder melanoma is even rarer than described in the literature, and the question whether this entity really exists remains open.

Second primary melanoma in advanced melanoma patients treated with anti-PD-1 monoclonal antibodies.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e22025-e22025
Author(s):  
Elisa Funck-Brentano ◽  
Estelle Charvet ◽  
Louise Chaplain ◽  
Amelie Gantzer ◽  
Oula Kassem ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Metastatic Melanoma ◽  
Braf Inhibitor ◽  
Primary Melanoma ◽  
Advanced Melanoma ◽  
Heterozygous Mutation ◽  
Second Primary ◽  
Exon 2 ◽  
Mutational Status ◽  
Melanoma Patients

e22025 Background: Development of a second primary melanoma (SCPM) has not been reported in melanoma patients treated with anti-PD-1 monoclonal antibodies (mAb), in contrast with those reported in BRAF-inhibitor-treated patients. Our aim was to report arising SCPM in patients with advanced melanoma treated with anti-PD-1 therapy. Methods: Retrospective study, conducted in 2 referral centres, including advanced melanoma patients who developed a SCPM after anti-PD-1 mAb initiation, between September 2010 and May 2019. BRAF or NRAS mutational status was assessed by targeted NGS panels, real-time PCR, and immunohistochemistry. Results: Among a total of 509 patients treated with anti-PD-1 mAb, 4 had a SCPM (incidence: 0.8%; 95%CI: 0.02-1.57%). All patients were treated with nivolumab, in first (N = 3) or second line after progression with BRAF + MEK inhibitors (N = 1). No immune-related adverse event greater than grade 2 according to Common Terminology Criteria for Adverse Events version 5.0. was observed in these 4 cases; a vitiligo-like depigmentation (grade 1) was observed in two patients. The median time from the first nivolumab infusion to the SCPM diagnosis was 17.5 months (range: 5-21). All patients developed the SCPM after achieving a complete response. Nivolumab administration had been discontinued (4 months prior) in one patient. Histology revealed 4 superficial spreading melanomas (SSM): one invasive (without BRAFV600 mutation) and 3 intraepidermal melanomas (2 with a BRAFV600E mutation and one with a NRASQ61H mutation). 3 patients had risk factors for developing multiple melanomas: a dysplastic nevus syndrome, a high number of nevi (≥100 nevi), and a family history of melanoma in first-degree relatives and constitutional heterozygous mutation of exon 2 of the CDKN2A gene. Occurrence of SPCM did not alter advanced melanoma treatment. With a median follow-up of 29 months [range: 18-41] from the first anti-PD-1 mAb infusion, all patients had prolonged CR, and treatment was discontinued in all patients, without relapse after a median 11.5 months [0-18] off therapy. The median duration of nivolumab treatment was 15.5 months [10-24]. Conclusions: Although anti-PD-1 mAb could theoretically decrease the risk of developing another melanoma in metastatic melanoma patients, we found 4 such cases, highlighting the importance of regular clinical screenings for new primary melanoma in patients with metastatic melanoma even when responsive to anti-PD-1 therapy. Immune checkpoint inhibitors do not totally prevent the risk of occurrence a SCPM.

Sign in / Sign up

Export Citation Format

Share Document